shandong luoxin pharmacy stock ltd. co

Shandong Luoxin Pharmacy Stock Co., Ltd. was reformed from Shandong Luoxin Pharmaceutical Factory and controlled by Linyi Luoxin Medicine Co., Ltd. and jointly funded by the 11 enterprises including Shenyang Pharmacy University ect. Shandong Luoxin is a pharmaceutical enterprise established in accordance with modern enterprise system and national GMP standard. It was accredited as a High and New Technology Enterprise by Shandong Province Science and Technology Committee in March 2003. Shandong Luoxin is principally engaged in the research, development, production and sales of Chinese and Western medicine and raw medicines. With more than 30 GMP-certified production lines for lyophilized powder for injection preparation, powder for injection preparation, solid preparation, chemical raw medicine, cephalosporins raw medicine and orally-taken cephalosporins series products in place, the Group has an annual production capacity of 500 million pieces of powder for injection preparation; 160 million pieces of lyophilized powder for injection preparation; 2.5 billion tablets; 2 billion granules of capsules; 300 million packs of granule preparation; 80 million packs of Dry Suspension preparation; 300 tons of cephalosporins raw medicine; and 100 tons of other chemical raw medicine. Persisting with the strategy of focusing on science and technology advancement, Shandong Luoxin, supported by the solid research skills of the Shenyang Pharmacy University and itself, under the product strategy of producing one generation, storing one generation, and researching one generation, has continued to promote 3-High - High-tech Ingredient, High Quality and High Value-addedproducts. Currently, the Group has launched more than 240 products in the market, with the production scale of cephalosporins series products to be including the compounding of original material and sub-packaging of powder for injection preparation, which secures product quality. The technological innovation brings into the products' innovation, a large quantities of state class new medicine came out and has filled up the domestic blank. The state class 1 new medicine Luoxin Yanda (Gatifloxacin for Injection) have filled up the gaps of powder for injection preparation production in Linyi city , filled up the gaps of lyophilized powder for injection preparation production, and also filled up the gaps of state class 1 new medicine. The company has been implementing the sales strategy of creating famous brand with science and technology, improving enterprise reputation with famous products and driving sale of products with reputation, which has established the solid stamina and the foundation for the enterprise development. Shandong Luoxin has been an industry leader in various economic indexes in Shandong Province and has obtained favorable economic and social benefits. Numerous products have been granted the High and New Technology Advancement Awardin Shandong Province, traditional Chinese medicine lyophilized powder for injection preparation Fushi Kelin has been granted the patent right, the protection period is 20 years. The company has been valued as €œAAA‘ € grade honorable enterprise by the Ministry of Commerce in China, and the Luoxintrademark is elected as Chinese Well-known Trademark by the State Administration for Industry and Commerce of the PRC, and the company has also been appraised as Provincial AAA-Grade Credible Enterprise, Contract-Integrity Enterprise, Civilized Unitand Advanced Unit in Medical Industryat the province and city level for many times. Luoxin Pharmacy has entered the Top 100 Pharmaceutical Enterprises of China, and Top 10 Most Potential Pharmacy Enterprises of Chinasince market network of Luoxin Pharmacy is all over China now. Luoxin Pharmacy owns independent right of import and export, and has listed its H shares on HKEx in 2005, making a delightful stride into the international market, thus the company is developing into a new milestone. In order to find a foothold in the inconstant market and boost the company to continuously and rapidly develop, Luoxin Pharmacy is fully implementing the business strategy and development program of the 11th 5-year-plan. During the period of the the 11th 5-year-plan, the overall mission of Shandong Luoxin is to implement the strategy named 1271030, aiming at enhancing onecapability (the core competitive ability is to absorb and cultivate outstanding talents, in order to provide the largest room of value for clients); accelerating twoadvancements (striving for patents, exclusive 3-Highproducts, high-end and standardized production domain of antibiotics); strengthening seveninnovations (novel idea, novel system, novel technology, novel management, novel mechanism, novel market development and novel exploration on human resources), and the management goal is increasing 30% every year based on 2006. According to the requirements of clear intellectual property, duties and responsibilities, and scientific management, Luoxin Pharmacy has continuously established 7 major systems, namely (1) a standardized, flexible, coordinative and modernized enterprise management system; (2) an innovative cultural system of common objective and value orientation; (3) an effective enterprise organization system; (4) a capital operation system with capital expansion and financing combined; (5) a high-tech, innovative system for sustainable development of new medicines; (6) an inspiring and restrictive human resources assurance system; and (7) a dynamic and competitive marketing and sales system. In the tide of reform, Luoxin Pharmacy is braving in the wind and the waves, marching forward and has made great achievements. Luoxin will become a symbol of success and health, which is our consistent wish and will also become the aim of the enterprise's development. With the principle of credit first and the Guiding ideology of reform and innovation, we constantly provide the largest room of value for clients. We will insist to provide the customers with high quality, lower price products and excellent services. We'd like to cooperate with colleagues of medical industry for mutual development.